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Background: Since a phase I clinical trial using three HLA-A24-binding peptides from TTK protein kinase (TTK),
lymphocyte antigen-6 complex locus K (LY6K), and insulin-like growth factor-II mRNA binding protein-3 (IMP3) had
been shown to be promising for esophageal squamous cell carcinoma (ESCC), we further performed a multicenter,
non-randomized phase II clinical trial.
Patients and methods: Sixty ESCC patients were enrolled to evaluate OS, PFS, immunological response employing
ELISPOT and pentamer assays. Each of the three peptides was administered with IFA weekly. All patients received
the vaccination without knowing an HLA-A type, and the HLA types were key-opened at the analysis point. Hence,
the endpoints were set to evaluate differences between HLA-A*2402-positive (24(+)) and -negative (24(−)) groups.
Results: The OS in the 24 (+) group (n = 35) tended to be better than that in the 24(−) group (n = 25) (MST 4.6 vs.
2.6 month, respectively, p= 0.121), although the difference was not statistically significant. However, the PFS in the
24(+) group was significantly better than that in the 24(−) group (p= 0.032). In the 24(+) group, ELISPOT assay
indicated that the LY6K-, TTK-, and IMP3-specific CTL responses were observed after the vaccination in 63%, 45%,
and 60% of the 24(+) group, respectively. The patients having LY6K-, TTK-, and IMP3-specific CTL responses revealed
the better OS than those not having CTL induction, respectively. The patients showing the CTL induction for
multiple peptides have better clinical responses.
Conclusions: The immune response induced by the vaccination could make the prognosis better for advanced
ESCC patients.
Trial registration: ClinicalTrials.gov, number NCT00995358
Keywords: Cancer vaccine, Esophageal cancer, Phase II clinical trial, CTL, Peptide vaccine* Correspondence: surkoji@nus.edu.sg
1First Department of Surgery, University of Yamanashi, Yamanashi, Japan
10Department of Surgery, National University of Singapore, Level 8, NUHS
Tower Block, NUHS 1E Kent Ridge Road, 119228, Singapore, Singapore
Full list of author information is available at the end of the article
© 2012 Kono et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.
Kono et al. Journal of Translational Medicine 2012, 10:141 Page 2 of 9
http://www.translational-medicine.com/content/10/1/141Background
Recent approval of Sipuluecel-T, which is cancer vaccine
with an activated antigen presenting cells and lymphocyte
mixture for hormone refractory prostate cancer and anti-
CTLA4 mAb (Ipilimimab) for melanoma implicate a new
era of the immunotherapy in the anti-cancer strategy
[1,2]. Therapeutic cancer vaccines against tumor-specific
antigens have suggested the improvement of patient`s sur-
vivals [1-4]. Moreover, several phase III randomized trials
of cancer vaccination with various tumor antigens against
different types of tumor are on-going [5].
We previously reported that three novel HLA-A24-
restricted immunodominant peptides, which were
derived from three different Cancer-Testis antigens,
TTK protein kinase (TTK), lymphocyte antigen 6 com-
plex locus K (LY6K), and insulin-like growth factor
(IGF)-II mRNA binding protein 3 (IMP-3), were promis-
ing targets for cancer vaccination for ESCC patients [6]
because of their specific and frequent expression in
tumor tissues [6-12]. Since these three genes were also
shown to be essential for cancer cell growth/survival, a
possibility of immune escape of cancer cells by losing
protein expression is very low. Moreover, it has shown
that these three peptides could stimulate CTLs that
recognized and killed ESCC cells endogenously expres-
sing these antigens [7] and that pre-existence of specific
T cells, which could respond to the peptides derived
from TTK, LY6K, and IMP3, were present in tumor-
infiltrating lymphocytes (TIL), regional lymph node lym-
phocytes (RLNL), and PBLs obtained from HLA-A*2402
positive patients with ESCC [12]. Therefore, we had per-
formed a phase I clinical cancer vaccination trials with a
combination of multiple peptides that were derived from
TTK, LY6K, and IMP3 for the HLA-A*2402 (+) patients
with advanced ESCC who had been refractory to stand-
ard ESCC therapy, and the evidence in the phase I trial
encouraged us to further develop this therapy as a phase
II trial [6].
In the present report, we evaluated the survival benefit
of the cancer vaccination and immunological monitoring
in the phase II study for the patients with advanced
ESCC who had been refractory to standard therapy.
Materials and methods
Study design
The present study is phase II, open-label, non-
randomized, multicenter (7 centers in Japan) cancer vac-
cine trial as an exploratory setting. All enrolled patients
had received the vaccination without knowing HLA-A
status, and the HLA-A genotypes were used for key-
open at analysis point. The endpoints were evaluated by
differences between HLA-A*2402-positive (24(+)) and -
negative (24(−)) groups as a biological marker for the
sub-group analysis. Vaccination with a mixture ofmultiple peptides, that were derived from TTK, LY6K,
and IMP3, and incomplete Freund’s adjuvant (IFA; Mon-
tanide ISA51, SEPPIC) was performed to the ESCC
patients (n = 60) with locally advanced, recurrent, or/and
metastatic tumors who had been resistant to standard
therapy. HLA-A genotyping in all enrolled patients was
performed by middle resolution genotyping method at
HLA Laboratory (Kyoto, Japan).
The primary endpoint for evaluation in this study was
overall survivals (OS). The secondary endpoint was pro-
gression free survivals (PFS), immunological responses,
and adverse effects. Toxicities caused by the vaccination
therapy were assessed by Common Terminology Criteria
for Adverse Events version 3 (CTCAE). Immunological
monitoring was performed at the central laboratory by
both enzyme-linked immunospot (ELISPOT) assay and
a pentamer assay using in vitro culturing lymphocytes
derived from PBLs at pre- and post-vaccination periods,
as described below. The OS, which was measured in
days from the 1st vaccination to death, was analyzed by
the Kaplan-Meier method, and the PFS was measured in
days from the1st vaccination to disease progression.
We estimated that 29 patients in the 24 (+) group and
20 patients in the 24(−) group would be required by the
assumption of a survival rate at 6 months of 30% in the
24(−) group and 45% in the 24(+) groups with overall
alpha levels of 0.2 and beta levels of 0.5 as an explora-
tory setting. Considering the distribution (about 60%) of
HLA-A*2402 in the Japanese population [13] and some
drop-out cases, we decided to enroll a total of 60
patients.
The evaluation of endpoints was performed by
intention-to-treat analysis. This study was approved by
the institutional review board at each University (Ap-
proval Number at University of Yamanashi of Principal
Investigator, No.484) and was registered with Clinical-
Trials.gov, number NCT00995358. Written informed
consent was obtained from all participants. The trial was
carried out in accordance with the Helsinki declaration
on experimentation on human subjects.
Patient eligibility
The eligibility criteria of patients participating in the
clinical trial were as follows. A) ESCC patients with lo-
cally advanced, recurrent, or/and metastatic tumors who
had failed to respond to the standard therapy; B); Ad-
equate bone-marrow, cardiac, pulmonary, hepatic, and
renal functions including WBC of ≥2,000/mm³, platelet
count of ≥75,000/mm³, total bilirubin of ≤2.0 of the in-
stitutional normal upper limit, AST, ALT, ALP of less
than 2.5 times of the institutional normal upper limits,
creatinine of ≤1.5 of the institutional normal upper limit;
C) No therapy in 4 weeks prior to the initiation of the
trial: D) ECOG performance status of 0–2; and E) age of
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ticipating in the clinical trial were as follows. A) Preg-
nancy (women of childbearing potential: refusal or
inability to use effective means of contraception); B)
Breastfeeding; C) Serious bleeding disorder; D) Serious
infections requiring antibiotics; E) Concomitant treat-
ment with steroids or immunosuppressing agent; and F)
Decision of unsuitableness by principal investigator or
physician-in-charge.
Treatment protocol
Each of the three peptides (1 mg each) was emulsified in
1 ml IFA, and injected into bilateral sites of the neck or
inguinal at three separate regions. The vaccination was
given subcutaneously once a week for five weeks as a 1
cycle and, after the 2 week interval, the next cycle was
performed and continued as a monotherapy until the
judgment of PD or doctor’s assessment. For the im-
munological evaluation, PBLs were obtained from the
patients at the pre-vaccination period as well as after the
5th and 10th vaccinations. For the imaging analysis, CT
scan was performed at pre-vaccination period (within
1 month before vaccination) and every 2 months after
the vaccination.
Peptides
Peptides derived from TTK-567 (SYRNEIAYL), LY6K-
177 (RYCNLEGPPI), and IMP3-508 (KTVNELQNL) that
bound to an HLA-A24 molecule were synthesized as
described elsewhere [6]. The purity (>97%) of the pep-
tides were determined by analytical high-performance li-
quid chromatography (HPLC) and mass spectrometry
analysis, respectively. The endotoxin levels and biobur-
den of these peptides were tested and determined to be
within acceptable levels as GMP grade for the vaccines
(NeoMPS, Inc., San Diego).
Lymphocyte preparation for immunologic monitoring
The performance of the immunological assay at the
center laboratory was periodically standardized and vali-
dated by Clinical Laboratory Improvements Amend-
ments (CLIA) and the International Conference on
Harmonization of Technical Requirements for Registra-
tion of Pharmaceuticals for Human use (ICH) guide-
line [14,15].
PBLs were obtained from the patients at the pre-
vaccination period and after the 5th and 10th vaccina-
tions. Peripheral blood was taken by venipuncture,
collected in EDTA tube and transferred to the center
laboratory within 24 hrs at room temperature. Within
24 hrs from blood collection, PBLs were isolated with
Ficoll-Paque Plus (GE Healthcare Bio-sciences, Piscat-
away, NJ) density gradient solution and were stored at
−80 °C in cell stock media (Juji field) without serum at 5x 106 cells/ml. After thawing, cell viability was confirmed
to be more than 90% by trypan-blue dye.
For the in vitro culture, PBLs were thawed simultan-
eously and 5 × 105 cells per well were incubated in
medium with 100 units/ml of recombinant IL-2 (rIL-2;
Novartis) with the peptide stimulation (10 μg/ml) twice
on day 1 and day 8 in combination with HIV-specific
peptide (ILKEPVHGV, 10 μg/ml) as a negative control
and CMV-specific peptide (RYLRDQQLL, 10 μg/ml) as
a positive control. On day 15, the cultured lymphocytes
were subjected to ELISPOT assay after depletion of CD4
cells by magnetic beads (Invitrogen, Grand Island, NY).
For the 24(+) group, the conventional ELISPOT assay
with TISI cells, which is human B-lymphoblastoid cells
expressing HLA-A24 on their surface, pulsed with the
relevant peptide as targets in combination with irrele-
vant HIV-specific peptide were performed, and followed
by the HLA-A24 Pentamer assay. For the 24(−) group,
modified ELISPOT with dump assay in the absence of
APC as described below.
ELISPOT assay
To monitor antigen-specific immune response, ELI-
SPOT assay was performed with the human IFN-γ ELI-
SPOT PLUS kit (Mabtech, Nacka Strand, Sweden). 96-
well plates with nitrocellulose membranes (Millipore,
Molshelm, France) were pre-coated with primary anti-
IFN-γ antibody (1-D1K) at 4 °C overnight. The plates
were then pre-reacted with RPMI medium containing
10% FBS (Invitrogen). For the 24 (+) group, each vaccine
peptide (10 μg/ml)-, HIV-specific peptide (ILKEPVHGV,
10 μg/ml)- or CMV-specific peptide (RYLRDQQLL,
10 μg/ml)-pulsed TISI cells (2 × 104/well) as stimulators
were incubated for 24 hrs in triplicate with responder
cells (from 2× 104/well to 2.5 × 103/well) in a total of
200 μl/well in different responder/stimulator ratios as
indicated. The stimulation with phorbol 12-myristate
13-acetate (PMA, 25 ng/mL, Sigma-Aldrich, St. Louis
MO) + ionomycin (500 pM, Sigma-Aldrich) was used as
a positive control for T cell activity. For the 24(−) group,
responder cells (2 × 104/well) and each peptide (10 μg/
ml) or HIV-specific peptide (10 μg/ml) in a total of
200 μl/well were cultured without APC for 24 hrs in
triplicate in combination with PMA+ ionomycin as a
positive control. These cell mixtures were treated with
biotinylated secondary anti-IFN-γ antibody (7-B6-1) and
incubated for 2 h. Then the plates were incubated with
HRP-reagent and stained with TMB (Mabtech). The
spots were quantified with an auto-analyzing system,
ImmunoSPOT S4 (Cellular Technology Ltd). Positivity
of antigen-specific T cell response was quantitatively
defined according to our original evaluation tree algo-
rithm (Additional file 1: Figure S1). In brief, the peptide-
specific spots were the average of triplicates by
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the immunized peptide-pulsed stimulator well. The posi-
tivity of antigen-specific T cell response were classified
into four grades (−, +, ++, and +++) depending on the
amounts of peptide-specific spots and invariability of
peptide-specific spots at different responder/stimulator
ratios. When the algorithm indicated +, ++, or +++ at ei-
ther 5th or 10th vaccination point, we judged to be posi-
tive case.
Pentamer assay
For the 24(+) group, the in vitro cultured T cells were
subjected to the pentamer assay to confirm the peptide-
specificity. HLA-A24/TTK-, HLA-A24/LY6K-, or HLA-
A24/IMP3-peptide pentamer (ProImmune) staining in
the combination with CD8 and CD3 mAbs were per-
formed and analyzed with flow cytometry.
Statistical analysis
OS and PFS were analyzed by the Kaplan-Meier method,
and the statistical differences were analyzed by Log-rank
method. All statistical analyses were performed with
SPSS statistics 17.0 (SPSS Inc.).
Results
Patient background
We recruited 60 eligible patients between October 1st,
2008 and April 3rd, 2010. The study database was locked
on May 25, 2011. Expectedly, 58% of the enrolled
patients possessed HLA-A*2402 (n = 35) and 42% of
them were negative for HLA-A*2402 (n = 25) (Table 1)
as similar to the reported allelic frequency in the Japa-
nese population [13]. The backgrounds of the patients
were not statistically different between the 24(+) and 24
(−) groups as shown in Table 1. The analysis for all en-
rolled patients (n = 60) was performed by Intention-to-
treat (ITT), although one patient in the A24 (+) group
and one patient in the A24(−) group did not follow the







Age(year) 61.8±7.6 62.3±7.1 61.1±8.2 NS
Male: Female 53/7 32/3 21/4 NS
Prior therapy
Operation 29(48%) 19(54%) 10(40%) NS
Radiation 48(80%) 26(74%) 22(88%) NS
Chemotheraphy
5FU 59(98%) 35(100%) 24(96%) NS
CDDP 58(97%) 33(94%) 23(92%) NS
Docetaxel 54(90%) 31(91%) 23(92%) NS
NS not significant between the HLA-A24(+) and HLA-A24(-) group.OS and PFS
The OS and PFS in all enrolled patients after the vaccin-
ation were shown in Figure 1A and 1B. When the
patients were classified into the 24(+) and 24 (−) groups,
the OS in the 24(+) group tended to be better than that
in the 24(−) group (4.6 vs. 2.6 month at MST, respect-
ively, p= 0.121, Figure 2A), although the difference of
OS was not statistically significant. However, the PFS in
the 24(+) group was significantly better than that in the
24(−) group (p= 0.024, Figure 2B).
OS in A24 (+) group related to Immunological monitoring
For the A24 (+) group, in vitro cultured T cells were
subjected to the ELISPOT and pentamer assays. Repre-
sentative ELISPOT and pentamer assays specific to the
LY6K peptide were shown in Figure 3. The ELISPOT
assay indicated substantial T cell responses specific to
the LY6K peptide in comparison to the irrelevant pep-
tide (Figure 3A) according to the criteria described in
Materials and Methods. This LY6K-specific T cell re-
sponse was further confirmed by the LY6K-pentamer
assay as shown in Figure 3C with the value of 17.95% of
pentamer (+) +CD8(+) among CD3(+) cells.
In the 24(+) group, the positive CTL responses specific
for the LY6K-, TTK-, and IMP3-peptide after the vaccin-
ation were observed in 63%, 45%, and 60% of theFigure 1 Overall survival (OS) and progression free survival
(PFS) in all enrolled patients. The OS (A) and PFS (B) were
analyzed by the Kaplan-Meier method. OS was measured in days
from the 1st vaccination to death and the PFS were measured in
days from the1st vaccination to disease progression.
Figure 2 Overall survival and progression free survival of the
A24(+) and A24(−) groups. All enrolled patients had received the
vaccination without knowing HLA-A status, and the HLA-A
genotypes were used for the key-open at analysis point. The OS (A)
and PFS (B) were evaluated for each of the HLA-A*2402-positive (24
(+)) and -negative (24(−)) groups for the sub-group analysis. MST,
median survival time.
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cells in the cultured T cells were all confirmed by the
pentamer assays for the LY6K-, TTK-, and IMP3-peptide
as 9.5-17.8%, 6.0–20.1%, and 5.1–15.5% of the positive
cells, respectively in the value of pentamer (+) +CD8(+)
among CD3(+) cells.
When the OS was compared between the patients with
CTL response (+) and (−) in the A24(+) group, the
patients having CTL response specific to the LY6K pep-
tide revealed significantly better OS than those without
LY6K-specific CTL responses (Figure 4A). Similarly, the
patients showing positive responses specific to the TTK
peptide revealed significantly better OS than those with-
out CTL responses (Figure 4B). OS of the patients with
IMP3-specific CTL responses tended to be better than
those without CTL responses, although the difference
was not statistically significant (Figure 4C). Interestingly,
when the patients were divided into 4 groups according
to the number of antigens that they showed the positive
responses, OS seemed to be better in the patient groupsthat showed the positive reaction to a larger number of
the peptides (Figure 5); MST of the patients having CTL
responses to all of three peptide was better (7.5 month)
than those of other patient groups (Figure 5). Thus,
these observations indicated that the immunological re-
sponse induced by the peptide vaccination contribute to
the improvement of prognosis of the patients.
Immunological evaluation in the A24(−) group
In vitro cultured T cells from all patients of the A24 (−)
group were subjected to the modified ELISPOT assay by
applying the dump assay (the ELISPOT assay was per-
formed without antigen presenting cells). A representa-
tive ELISPOT assay detected a presence of LY6K-
peptide-specific T cells in in vitro cultured T cells (Add-
itional file 2: Figure S2A) and their quantification experi-
ment indicated positive CTL induction according to the
criteria (Additional file 2: Figure S2B).
Through the modified ELISPOT assay, 3 (12%) of the
25 A24(−) patients were considered to have the peptide-
specific CTL response against any of three antigens.
Three patients with HLA-A*0201/-A*0301, HLA-A
*0201/-A*0201 or HLA-A*0206/-A*3303 responded to
the LY6K-peptide. This observation might reflect the
cross-reactivity to a different HLA allele(s) against the
vaccinated peptides in the present study. It might be
notable that these three patients showed better OS in
comparison to the patients with the ELISPOT-negative
result in the 24(−) group (data not shown). Moreover,
when the patients having the peptide-specific CTL re-
sponse in the 24(−) group were excluded from the 24(−)
group in the OS analysis, the OS in the 24(+) group
(n = 35) were significantly better than those of the 22
patients in the 24(−) group (Additional file 2: Figure
2 C).
Adverse reactions
The vaccination therapy was well-tolerated without any
treatment-associated adverse events of grade 3 or higher.
Thirty-two of the 60 patients developed grade 1 or 2
local skin reactions with redness and swelling in the in-
jection sites. High grade fever, fatigue, diarrhea, head-
ache, rash, and itching were not observed in any
patients. No hematologic, cardiovascular, hepatic, or
renal toxicity was observed during or after the
vaccination.
Discussion
The present phase II clinical study demonstrated that
vaccination-induced immune response positively corre-
lated with the better prognosis in advanced ESCC
patients, implying that the cancer vaccine treatment
with multi-epitope peptides as a monotherapy might
provide the clinical benefit to the patients. To our
Figure 3 Representative immunological monitoring assays detecting antigen-specific CTL response in a patient belonging to the 24(+)
group. PBLs obtained from case 2 patient (HLA-A*2402 positive) after the 10th vaccination were cultured in rIL-2 for 14 days with 2 times of LY6K-
peptide stimulation. (A) The cultured lymphocytes were subjected to the ELISPOT assay after depletion of CD4-positive cells by magnetic beads.
TISI cells were incubated with responder cells in the presence of LY6K peptide or HIV peptide as an irrelevant control, and the spot counts were
quantified (B). (C) The cultured lymphocytes were analyzed with HLA-A2402/LY6K-pentamer in the combination with CD8 and CD3 mAbs with
flow cytometry. The value of pentamer (+)/CD8(+) among CD3(+) cells was shown. R/S, responder/stimulator.
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sult indicating that therapeutic cancer vaccination with
multiple peptides may improve the prognosis of patients
with advanced solid tumors who had failed to standard
therapy.
Several phase II and III clinical trials have recently
demonstrated the promising and the therapeutic poten-
tials of cancer vaccination [1-5,16-19]. However, most of
them are performed with single antigen-based vaccin-
ation with several modifications and the clinical benefit
seems to be very limited. In order to further improve the
clinical responses of cancer vaccination treatment, it is
necessary to consider the application of a combination
of multiple vaccines derived from the different target
molecules, because it may overcome the issue of hetero-
geneity of tumor cells and also avoid the escape of
tumor cells from peptide-specific immune response by
loss of antigen expression [5,20]. In general, the prefer-
able characteristic of the target molecules for develop-
ment of cancer vaccines are (1) high immunogenicity,
(2) very common expression in cancer cells, (3) specific
expression in cancer cells and (4) essential molecules for
cell survival (to avoid loss of expression) [5,20]. In this
regard, TTK, LY6K, and IMP3 molecules used in thepresent trials are considered to be most appropriate be-
cause they were expressed in the great majority (> 95%)
of esophageal cancers, were expressed specifically in
cancer cells and testis (cancer-testis antigens), were
shown to be essential for survival of cancer cells, and
most importantly revealed very strong immunogenicity
[6-12].
In the present phase II clinical trial, we compared the
OS and PFS between the A24(+) and A24(−) groups
classified by the HLA-A*2402 positivity as a biological
marker. The PFS and, less significantly, OS in the A24
(+) group were better than those in the A24(−) group,
suggesting that the therapeutic cancer vaccine treatment
using the HLA-A24-restricted peptides could induce
some survival benefits for advanced ESCC patients. Fur-
thermore, in the A24 (+) group, the specific CTL
responses to multiple peptides may improve OS in com-
parison with the cases with the CTL induction to no or
a single peptide. Although treatment with cancer vac-
cines had been shown to cause an increase of circulating
tumor antigen-specific T cells [21], we have here demon-
strated the direct evidence of positive correlation be-
tween the extent of peptide-specific CTL responses and
better OS. Hence, our present study supports the
Figure 4 OS in the A24 (+) group related to immunological
monitoring specific to each of the LY6K, TTK, and IMP3
peptides. In the 24(+) group, the in vitro cultured T cells were
subjected to ELISPOT assays. The positive CTL responses specific to
each of LY6K-, TTK-, and IMP3-peptides after the vaccination were
observed in 63%, 45%, and 60% of the patients, respectively. The OS
was compared between the patients with positive CTL response (+)
and those with negative CTL response (−) for each peptide, the
patients with positive CTL response specific to the LY6K-peptide
revealed significantly better OS than those without CTL response (A).
Similarly, the patients with positive CTL response specific to the TTK-
peptide showed significantly better OS than those without CTL
response (B). For IMP3, the patients with positive CTL response
specific to the peptide tended to have better OS than those without
CTL response, although the difference was not statistically significant
(C).
Figure 5 OS in the four subgroups of the A24 (+) group
classified by the number of the peptides showing the positive
CTL responses. The A24(+) patient group was classified into 4
groups according to the number of peptide antigens which induced
the CTL responses (0, 1, 2 and 3). The OS tended to be better when
the number of the peptides that induced CTL responses was higher.
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could contribute to the improvement of prognosis of
advanced ESCC patients.
According to the recommendation from the iSBSTc-
SITC/FDA/NCI Workshop on Immunotherapy Biomar-
kers [22-24], we have performed the immunological
monitoring in the A24 (+) group by two different assays,
ELISPOT and pentamer assays, at three different time
points and at the center laboratory. Since the peptides
used in the present study had strong immunogenicity,
the in vitro immunological monitoring in the A24 (+)
group was successfully performed in a reliable way.
In the 24(−) group, the modified ELISPOT assay with-
out APC suggested that the cross-reactivity with thedifferent HLA allele(s) against the vaccinated peptides
may exist in some extent. Although the modified ELI-
SPOT assay in the 24(−) group was not fully standar-
dized due to lack of APC and appropriate positive
controls, we suspect that this cross-reactivity in patients
in the 24(−) group might influence the clinical outcome.
Three patients with positive ELISPOT assays did not
have a common HLA-A allele genotype, but two of them
had HLA-A*0201 and the other had HLA-A*0206 that is
known to structurally similar to HLA-A*0201. Although
the LY6K-peptide used in the present clinical trial is pre-
dicted to have a weak-binding affinity to HLA-A0201 by
BIMAS and NetMHC programs, the peptide might
cross-react to HLA-A0201 and their structurally similar
HLA. Further study to clarify whether the LY6K-peptide
could actually bind to HLA-A0201 and the other HLA
molecules, and whether the immunogenicity in context
with HLA-A0201 is confirmed by CTLs will be needed.
Since available cancer vaccines probably are likely to
be applied as adjuvant treatment for the patients who
are at high risk of relapse following surgical resection of
primary tumor [5,20], and we are planning to develop
these cancer vaccine as an adjuvant setting for ESCC
patients with a lymph node metastasis after curative eso-
phagectomy. However, even if the patients are at an
advanced stage and have been intensively treated with
chemotherapy and/or radiotherapy, the present study
indicated that cancer vaccine may provide some clinical
benefit as a monotherapy without any severe side effects.
In general, there is no curative therapy for ESCC
patients with in-operable tumor or those with recur-
rence after surgery. Platinum-based regimens including
5FU, CDDP and Taxans have been used as the first line
chemotherapy for these patients, but the median survival
time of such patients was as short as 7–8 months
[25,26]. However, there is no effective treatment
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the first line chemotherapy. Hence, we are confident that
our protocol should be promising for improvement of
the prognosis and quality of life even for advanced ESCC
patients.
Conclusions
To our knowledge, this study is the first to show the
proof of concept that vaccination-induced immune re-
sponse could provide the better prognosis in advanced
ESCC patients and has implied that cancer vaccine treat-
ment with multiple peptides as monotherapy can be a
hope to patients with advanced solid tumors who had
failed to standard therapy.
Additional files
Additional file 1: Figure S1. Positivity of antigen-specific T cell
response was quantitatively defined according to the evaluation tree
algorithm. In brief, the peptide-specific spots (SS) were the average of
triplicates by subtracting the HIV peptide-pulsed stimulator well from the
immunized peptide-pulsed stimulator well. The %SS means the
percentage of SS among the average spots of the immunized peptide-
pulsed stimulator well. The positivity of antigen-specific T cell response
were classified into four grades (−, +, ++, and +++) depending on the
amounts of peptide-specific spots and invariability of peptide-specific
spots at different responder/stimulator ratios. For example, the ELISPOT
data from Figure 3 (SS = 480 at ratio 1, SS = 404 at ratio 0.5, SS = 292 at
ratio 0.25, and %SS = 74 at ratio 1, %SS = 88 at ratio 0.5) matched to the
criteria (1) and (2) in the first step and then, the data matched to criteria
(1) in the second step. Thus, the ELISPOT data was finally evaluated as (+
++). SS, peptide-specific spots; R1, responder/stimulator ratio = 1; R2,
responder/stimulator ratio = 0.5; R3, responder/stimulator ratio = 0.25; R4,
responder/stimulator ratio = 0.125.
Additional file 2: Figure S2. Immunological evaluation in the A24(−)
group. The in vitro cultured T cells from all patients of the A24 (−) group
were subjected to the modified ELISPOT assay by applying the dump
assay (the ELISPOT assay was performed without antigen presenting
cells). A representative ELISPOT assay detected a presence of LY6K-
peptide-specific T cells in in vitro cultured T cells (Additional file 2: Figure
S2A) and their quantification experiment indicated positive CTL induction
according to the criteria (Additional file 2: Figure S2B). Through the
modified ELISPOT assay, 3 (12%) of the 25 A24(−) patients were
considered to have the peptide-specific CTL response against any of
three antigens. When the patients having the peptide-specific CTL
response in the 24(−) group were excluded from the 24(−) group in the
OS analysis, the OS in the 24(+) group (n = 35) were significantly better
than those of the 22 patients in the 24(−) group (Additional file 2: Figure
S2C).
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